Vascular Center, Skåne University Hospital, Malmö, Sweden.
Vascular Center, Skåne University Hospital, Malmö, Sweden.
J Vasc Surg. 2014 Jan;59(1):115-20. doi: 10.1016/j.jvs.2013.07.009. Epub 2013 Sep 5.
To evaluate late outcomes after fenestrated endovascular aortic repair (f-EVAR) in a tertiary European referral center.
In 2009, we published short- and midterm results after f-EVAR in the first 54 patients treated with this technique at our center between September 2002 and June 2007. In this paper, we provide long-term follow-up of the same patient cohort with the main focus on target vessel (TV) patency, renal function, reinterventions, and survival.
A total of 54 patients were included in this study. Median age was 72 years (interquartile range [IQR], 68-76 years) at primary operation, and 85% were men. Median preoperative aneurysm diameter was 60 mm (IQR, 53-66 mm). One hundred thirty-four vessels were targeted (mean, 2.5 per patient), and 96 TV stents were placed. The median clinical follow-up was 67 months (IQR, 37-90 months), and computed tomography follow-up was 60 months (IQR, 35-72 months). Aneurysm diameter decreased ≥ 5 mm in 39% ± 7% at 12 months, 64% ± 8% at 36 months, and 71% ± 8% at 60 months. Primary TV patency was 94% ± 2% at 12 months, 91% ± 3% at 36 months, and 90% ± 3% at 60 months. Glomerular filtration rate decreased by 17% at 59 months (IQR, 26-73 months) follow-up (60 [IQR, 46-79] vs 50 [IQR, 38-72] mL/min/1.73 m(2); P < .001), and one patient became dialysis-dependent secondary to a renal stent occlusion. Reintervention-free survival was 88% ± 5% at 12 months, 69% ± 7% at 36 months, and 56% ± 5% at 60 months. At least one reintervention was done in 37% of patients, of which 29% were endoleak-related, 26% TV-related, 13% graft-limb-related, and 32% due to other causes. The majority of reinterventions (68%) were based on complications detected on routine follow-up. Estimated overall survival was 93% ± 4% at 12 months, 76% ± 6% at 36 months, and 60% ± 7% at 60 months. In total, 54% of the patients died during the 10-year study period, where 9% died of aneurysm-related causes.
Long-term mortality after f-EVAR is high, but most patients die from nonaneurysmal causes. Aneurysm-related mortality is associated with technical complications that can be reduced with increased experience. Reinterventions are common, and most complications are detected on routine follow-up.
评估在一家三级欧洲转诊中心进行开窗血管内主动脉修复(f-EVAR)后的晚期结果。
2009 年,我们发表了在我们中心于 2002 年 9 月至 2007 年 6 月期间接受该技术治疗的前 54 例患者的短期和中期结果。在本文中,我们提供了同一患者队列的长期随访,主要关注靶血管(TV)通畅性、肾功能、再干预和生存率。
共有 54 例患者纳入本研究。初次手术时的中位年龄为 72 岁(四分位距 [IQR],68-76 岁),85%为男性。术前中位动脉瘤直径为 60mm(IQR,53-66mm)。共定位 134 个血管(平均每个患者 2.5 个),放置 96 个 TV 支架。中位临床随访时间为 67 个月(IQR,37-90 个月),计算机断层扫描随访时间为 60 个月(IQR,35-72 个月)。12 个月时,动脉瘤直径减少≥5mm 的比例为 39%±7%,36 个月时为 64%±8%,60 个月时为 71%±8%。12 个月时 TV 通畅率为 94%±2%,36 个月时为 91%±3%,60 个月时为 90%±3%。肾小球滤过率在 59 个月(IQR,26-73 个月)随访时下降了 17%(60[IQR,46-79]vs.50[IQR,38-72]mL/min/1.73m2;P<0.001),1 例患者因肾支架阻塞而转为透析依赖。12 个月时无再干预生存率为 88%±5%,36 个月时为 69%±7%,60 个月时为 56%±5%。37%的患者至少进行了一次再干预,其中 29%与内漏有关,26%与 TV 有关,13%与移植物支腿有关,32%与其他原因有关。大多数(68%)再干预是基于常规随访中发现的并发症。估计 12 个月时的总体生存率为 93%±4%,36 个月时为 76%±6%,60 个月时为 60%±7%。在 10 年的研究期间,共有 54%的患者死亡,其中 9%死于动脉瘤相关原因。
f-EVAR 后的长期死亡率较高,但大多数患者死于非动脉瘤性原因。动脉瘤相关死亡率与技术并发症相关,随着经验的增加,这些并发症可以减少。再干预很常见,大多数并发症是在常规随访中发现的。